Avenue Therapeutics (NASDAQ:ATXI) was upgraded by equities research analysts at ValuEngine from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Monday, February 4th.
Separately, Oppenheimer set a $10.00 price target on shares of Avenue Therapeutics and gave the stock a “buy” rating in a report on Thursday, November 15th.
Shares of ATXI stock traded down $0.15 during trading hours on Monday, hitting $5.40. The company’s stock had a trading volume of 18,874 shares, compared to its average volume of 40,473. Avenue Therapeutics has a 12-month low of $2.08 and a 12-month high of $6.82. The company has a market capitalization of $57.62 million, a P/E ratio of -3.05 and a beta of -0.77.
In other news, Director Neil Herskowitz acquired 5,000 shares of the business’s stock in a transaction that occurred on Monday, February 25th. The stock was purchased at an average cost of $5.46 per share, for a total transaction of $27,300.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Jeffrey Paley acquired 15,000 shares of the business’s stock in a transaction that occurred on Monday, December 10th. The shares were purchased at an average price of $5.24 per share, with a total value of $78,600.00. The disclosure for this purchase can be found here. Insiders bought 40,947 shares of company stock valued at $225,030 over the last quarter. Company insiders own 5.00% of the company’s stock.
Institutional investors have recently added to or reduced their stakes in the stock. Northern Trust Corp acquired a new stake in Avenue Therapeutics during the fourth quarter worth about $79,000. National Asset Management Inc. boosted its stake in Avenue Therapeutics by 4.7% during the fourth quarter. National Asset Management Inc. now owns 66,250 shares of the company’s stock worth $358,000 after buying an additional 3,000 shares during the period. Finally, Opaleye Management Inc. purchased a new position in Avenue Therapeutics during the fourth quarter worth about $2,678,000. Hedge funds and other institutional investors own 2.07% of the company’s stock.
Avenue Therapeutics Company Profile
Avenue Therapeutics, Inc, a specialty pharmaceutical company, acquires, licenses, develops, and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, which is in Phase III clinical trials to treat moderate to moderately severe post-operative pain.
Recommended Story: What is a Tariff?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Avenue Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avenue Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.